| DIRECT COMPETITOR COMPARISON | |
| STEM | ACTC.OB | GERN | Pvt1 | Industry | | Market Cap: | 126.63M | 66.30M | 488.37M | N/A | 100.26M | | Employees: | 55 | N/A | 159 | N/A | 68 | | Qtrly Rev Growth (yoy): | 1,945.10% | 2.50% | 34.60% | N/A | 19.70% | | Revenue (ttm): | 747.39K | 1.03M | 1.66M | 100.00K1 | 14.01M | | Gross Margin (ttm): | 73.11% | 33.69% | N/A | N/A | 65.67% | | EBITDA (ttm): | -25.17M | -4.65M | -67.81M | N/A | -12.30M | | Oper Margins (ttm): | -3,569.49% | -489.45% | -4,178.08% | N/A | -149.46% | | Net Income (ttm): | -31.88M | -55.83M | -69.61M | -5.20M1 | N/A | | EPS (ttm): | -0.321 | -0.113 | -0.816 | N/A | -0.33 | | P/E (ttm): | N/A | N/A | N/A | N/A | 16.37 | | PEG (5 yr expected): | N/A | N/A | N/A | N/A | 1.31 | | P/S (ttm): | 169.43 | 64.29 | 293.32 | N/A | 9.35 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | 0.00% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | 0.00% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | 0.00% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | 0.00% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | 0.00% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | 0.00% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | 0.00% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | 0.00% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | 0.00% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | 0.00% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | 0.00% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | 0.00% | 107.13B | 13.42 | | Sanofi-Aventis | SNY | 38.43 | 0.00% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | 0.00% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | 0.00% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | 0.00% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | 0.00% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | 0.00% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | GERN | | 4-Star Stocks Poised to Pop: Cytori Therapeutics
Fri, Nov 27 -
at Motley Fool | | • | ACTC.OB | | ADVANCED CELL TECHNOLOGY, INC. Financials
Tue, Nov 24 -
EDGAR Online Financials | | • | ACTC.OB | | Advanced Cell Technology to Present at LD Micro Conference in Los Angeles
Tue, Nov 24 -
Business Wire | | • | ACTC.OB | | RPT-Company seeks to test stem cells for blindness
Thu, Nov 19 -
at Reuters | | • | ACTC.OB | | Advanced Cell Technology Files IND With FDA For First Human Clinical Trial Using Embryonic Stem Cells to Treat Eye Disease
Thu, Nov 19 -
Business Wire | | • | GERN | | Geron Presents Interim Clinical Data on Its Telomerase Inhibitor Drug at AACR-NCI-EORTC
Thu, Nov 19 -
Business Wire | | • | ACTC.OB | | ADVANCED CELL TECHNOLOGY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or
Tue, Nov 17 -
EDGAR Online | | • | GERN | | Geron to Present at LCM Healthcare Conference
Mon, Nov 16 -
Business Wire | | • | GERN | | Trading Outlook for StemCells Inc. Issued by InvestorSoup.com
Thu, Nov 12 -
GlobeNewswire | | | All Headlines for these symbols... |
|
|
|
1.48% Nasdaq 0.00%
Competitors
